Active, not recruitingPHASE1, PHASE2NCT06816498
Personalized Antisense Oligonucleotide Therapy for A Single Participant With LMNB1 Mutation Associated Autosomal Dominant Leukodystrophy (ADLD)
Studying Adult-onset autosomal dominant leukodystrophy
Last synced from ClinicalTrials.gov
ℹ
Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing dataKey facts
- Sponsor
- n-Lorem Foundation
- Intervention
- nL-LMNB1-001(drug)
- Enrollment
- 1 enrolled
- Eligibility
- 51-51 years · MALE
- Timeline
- 2025 – 2027
Study locations (1)
- Mayo Clinic, Rochester, Minnesota, United States
Collaborators
Mayo Clinic
Primary source
Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.
Open NCT06816498 on ClinicalTrials.gov